Shuttle Pharma signs $10M term sheet to buy Molecule assets; CRO Theradex terminates, seeks $1.09M

Shuttle Pharmaceuticals Holdings, Inc.

Binding term sheet for $10M purchase of substantially all assets and liabilities of Molecule; consideration in cash and stock per Shuttle's sole discretion, with milestones.
CRO Theradex terminated Master Agreement on Oct 15, 2025, demanding immediate payment of $1.091M; if unpaid in 30 days, services will cease.
Theradex is Shuttle's primary CRO; termination threatens clinical trial operations and requires immediate cash payment.
Transaction subject to due diligence, board approval, definitive agreements; exclusivity period of 90 days from Oct 20, 2025.
Shuttle intends to retain Molecule's CEO ZT Zhang for post-transaction transition and integration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.